MannKind (NASDAQ:MNKD) Sees Strong Trading Volume – Here’s What Happened

MannKind Corporation (NASDAQ:MNKD) saw strong trading volume on Wednesday . 5,397,284 shares changed hands during mid-day trading, an increase of 57% from the previous session’s volume of 3,441,796 shares.The stock last traded at $3.4730 and had previously closed at $5.54.

More MannKind News

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue beat and growth outlook — MannKind reported Q4 revenue of about $112M (+46% YoY) and management outlined a roughly $450M 2026 revenue run‑rate while preparing an Afrezza pediatric launch, which supports longer‑term upside. MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analyst keeps “overweight” despite cut — Wells Fargo trimmed its price target from $8 to $7 but maintained an overweight rating, signaling continued analyst conviction in upside even after the EPS miss. Wells Fargo price target note
• Neutral Sentiment: Heavy options activity — Reports show large volume of call option purchases in MNKD, which can amplify intraday moves and reflects some speculative bullish positioning but is not a guarantee of sustained upside. Investors Purchase Large Volume of MannKind Call Options
• Neutral Sentiment: Mixed metric readouts — Analysts note revenue comfortably beat estimates while EPS missed (-$0.05 vs. -$0.01 expected), leaving valuation/forward EPS expectations in flux—important context but mixed for immediate direction. MannKind Reports Q4 Loss, Tops Revenue Estimates
• Negative Sentiment: EPS miss and unexpected quarterly loss drove the sell‑off — The bottom‑line shortfall led to a sharp intraday drop and a 52‑week low as investors reacted negatively to the EPS miss despite revenue growth. Why MannKind Stock Tumbled on Thursday
• Negative Sentiment: RBC cut price target sharply — Royal Bank of Canada cut its target from $7.50 to $3.50 (sector perform), reducing near‑term analyst support and adding selling pressure. RBC rating/price target note
• Negative Sentiment: Broader biotech weakness — A sector‑wide pullback (“biotech bloodbath”) this week has dragged MNKD along with peers, amplifying downside from company‑specific negatives. Biotech Bloodbath Drags Health Care Down as MannKind and Soleno Stocks Sink
• Negative Sentiment: Competitive risk flagged — News that United Therapeutics is considering a new treprostinil formulation pressured MannKind (and peers), introducing potential product/market risk for inhaled/treprostinil formulations. United Therapeutics mulls new treprostinil formulation

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on MNKD shares. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of MannKind in a research report on Wednesday. Leerink Partners assumed coverage on shares of MannKind in a report on Thursday, November 13th. They issued an “outperform” rating and a $7.00 target price for the company. Royal Bank Of Canada reiterated a “sector perform” rating and set a $3.50 price target (down from $7.50) on shares of MannKind in a report on Friday. Truist Financial set a $9.00 price target on MannKind in a report on Monday, November 24th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of MannKind in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $9.21.

MannKind Stock Performance

The business has a 50 day moving average of $5.61 and a two-hundred day moving average of $5.35. The stock has a market capitalization of $1.01 billion, a PE ratio of 32.80 and a beta of 0.84.

MannKind (NASDAQ:MNKD) last announced its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.04). MannKind had a negative return on equity of 49.33% and a net margin of 9.32%.The firm had revenue of $111.96 million during the quarter, compared to the consensus estimate of $99.85 million. During the same quarter in the prior year, the firm posted $0.03 earnings per share. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. On average, equities analysts expect that MannKind Corporation will post 0.1 EPS for the current fiscal year.

Insider Buying and Selling at MannKind

In other news, insider Stuart A. Tross sold 47,006 shares of the stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $6.33, for a total transaction of $297,547.98. Following the completion of the sale, the insider owned 985,007 shares in the company, valued at approximately $6,235,094.31. This represents a 4.55% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Michael Castagna sold 107,920 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $5.57, for a total value of $601,114.40. Following the completion of the sale, the chief executive officer directly owned 2,504,792 shares of the company’s stock, valued at $13,951,691.44. The trade was a 4.13% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 262,846 shares of company stock worth $1,546,840 over the last ninety days. Corporate insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On MannKind

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in MannKind by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 17,880,873 shares of the biopharmaceutical company’s stock worth $101,385,000 after purchasing an additional 250,290 shares in the last quarter. State Street Corp raised its holdings in shares of MannKind by 36.2% in the fourth quarter. State Street Corp now owns 14,623,269 shares of the biopharmaceutical company’s stock worth $82,914,000 after buying an additional 3,883,071 shares during the last quarter. Rubric Capital Management LP acquired a new stake in shares of MannKind during the third quarter worth $61,297,000. Geode Capital Management LLC lifted its stake in shares of MannKind by 12.3% during the second quarter. Geode Capital Management LLC now owns 7,617,583 shares of the biopharmaceutical company’s stock worth $28,494,000 after buying an additional 831,478 shares during the period. Finally, UBS Group AG grew its holdings in shares of MannKind by 146.7% during the third quarter. UBS Group AG now owns 5,194,739 shares of the biopharmaceutical company’s stock valued at $27,896,000 after buying an additional 3,088,820 shares during the last quarter. Institutional investors and hedge funds own 49.55% of the company’s stock.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.